Exploring biomarkers in patients with combined allergic rhinitis and asthma syndrome
Preliminary Application and Evaluation of Exhaled Breath Condensate Biomarkers in Combined Allergic Rhinitis and Asthma Syndrome (CARAS)
This study is trying to find out if there are specific markers in the breath of people with combined allergic rhinitis and asthma syndrome that can help doctors better understand and treat their condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 270 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Henan University of Traditional Chinese Medicine Academic / other |
| Locations | 1 site (Henan, Zhengzhou) |
| Trial ID | NCT06573450 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the differences in biomarker expression between healthy individuals and those with combined allergic rhinitis and asthma syndrome (CARAS). It will utilize exhaled breath condensate samples to identify potential biomarkers associated with various stages of the disease and corresponding Chinese medicine symptoms. The study will involve a questionnaire survey to gather relevant data from participants who meet specific diagnostic criteria. The goal is to provide a foundation for individualized diagnosis and treatment approaches for CARAS.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with diagnosed allergic rhinitis, bronchial asthma, and CARAS who meet specific medical criteria.
Not a fit: Patients with other types of rhinitis, serious systemic diseases, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and personalized treatment options for patients suffering from CARAS.
How similar studies have performed: While the approach of using exhaled breath condensate for biomarker identification is gaining interest, this specific study's focus on CARAS is relatively novel and not extensively tested in prior research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with AR, BA and CARAS who meet the Western medical diagnostic criteria; * Chinese medical evidence consistent with lung qi deficiency evidence, phlegm-heat congestion of the lung evidence, or wind-heat offending the lung evidence; * Age 18 to 80 years; * Voluntarily accepted the study and signed an informed consent form; * Not participated in other clinical studies within 1 month before enrollment. Exclusion Criteria: * Patients with combined vasomotor rhinitis and eosinophilic non-allergic rhinitis, other non-allergic rhinitis diseases that can cause symptoms such as nasal congestion and runny nose; * Patients who are participating in other drug trials; * Patients with a combination of other serious systemic diseases; * Pregnant or lactating women; * Patients with confusion, disorders of consciousness, dementia, and various psychiatric disorders.
Where this trial is running
Henan, Zhengzhou
- The First Affiliated Hospital of Henan University of Chinese Medicine — Henan, Zhengzhou, China (Recruiting)
Study contacts
- Study coordinator: Yang Xie
- Email: xieyanghn@163.com
- Phone: 13526621325
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.